Somatostatin receptors in non-endocrine tumours

Digestive and Liver Disease

Volumn 36, Issue SUPPL. 1, 2004, Pages

  Smith, M C ^a   Maggi, M ^a   Orlando, C ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Breast cancer; Colorectal cancer; Neuroblastoma; Somatostatin receptors

Indexed keywords

MESSENGER RNA; OCTREOTIDE; PENTETREOTIDE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; STEROID; TAMOXIFEN;

ACCURACY; BREAST CANCER; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NEUROBLASTOMA; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; BREAST TUMOR; CHEMISTRY; COLORECTAL TUMOR; MORTALITY; NEOPLASM;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASMS; NEUROBLASTOMA; PROGNOSIS; RECEPTORS, SOMATOSTATIN;

EID: 2442699181     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2003.11.019     Document Type: Article

References (92)

1. Patel YC, Srikant C. Somatostatin receptors. Trends Endocrinol Metab 1997;8:398-405.
2. Woltering E, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1990;50:245-51.
3. Yamada Y, Post S, Wang K, Tager H, Bell G, Seino S. Cloning and functional characterisation of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992;89:251-5.
4. Yamada Y, Reisine T, Law S, Ihara Y, Kubota A, Kagimoto S, et al. Somatostatin receptors, an expanding gene family: cloning and functional characterisation of human SST3, a protein coupled to adenyl cyclase. Mol Endocrinol 1992;6:2136-42.
5. Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, et al. Cloning, functional expression and pharmacological characterisation of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993;195:844-52.
6. Buscail L, Esteve J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carrol AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by SSTR2 and SSTR5 somatostatin receptors through different mechanisms. Proc Natl Acad Sci USA 1995;92:1580-4.
7. Robbins RJ. Somatostatin and cancer. Metabolism 1996;45:98-100.
8. Lamberts SW, van der Lely A, Deherder WW, Hofland LJ. Drug therapy: octreotide. New Eng J Med 1996;334:246-54.
9. Schaer J-C, Waser B, Mengod G, Reubi J-C. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997;70:530-7.
10. Evans AA, Crook T, Laws SAM, Gough AC, Royle GT, Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997;75:798-803.
11. Radulovic SS, Milovanovic SR, Cai RZ, Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 1992;200:394-401.
12. Iftikhar SY, Thomas WM, Rooney PS, Morris DL. Somatostatin receptors in human colorectal cancer. Eur J Surg Oncol 1992;18:27-30.
13. Reubi JC, Schaer JC, Laissue J, Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996;45:39-41.
14. Bruns C, Stolz B, Raulf F, Scloos J, Weckbecker G. Somatostatin receptor expression: therapeutic considerations. J Endocrinol Invest 1997;20:2.
15. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27-35.
16. Foekens JA, Portengen H, van Putten WLJ, Trapman AMAC, Reubi JC, Alexieva-Figusch J, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 1989;49:7002-9.
17. Pollak MN, Schally AV. Mini review: Mechanism of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
18. Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 1995;210:805-15.
19. Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM. Somatostatin analogs in oncology: a look to the future. Chemotherapy 2001;47:162-96.
20. Casini Raggi C, Maggi M, Renzi D, Calabró A, Bagnoni ML, Scaruffi P, et al. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 2000;85:3866-73.
21. Santana WM. Neuroblastoma. In: Nelson E, Behrman RE, Kliegman RM, Arvin AM, editors. Textbook of pediatrics. Philadelphia: Saunders; 1996. p. 1460-3.
22. Castleberry RP. Neuroblastoma. Eur J Cancer 1997;33:1430-8.
23. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatrics oncology. Philadelphia: J. B. Lippincott; 1997. p. 761-97.
24. Evans AE, D'Angio GJ, Randolph JA. A proposed staging for children with neuroblastoma. Children's Cancer Study group A. Cancer 1971;27:374-8.
25. Zelter PM, Marangos PJ, Evans AE, Schneider SL. Serum neuron specific enolase in children with neuroblastoma. Cancer 1986;57: 1230-4.
26. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavorable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995;24:215-21.
27. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5.
28. Chan HSL, Haddad G, Thorner PS. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-14.
29. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Association between high risk levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma. N Engl J Med 1996;334:231-8.
30. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of MYCN in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
31. Tsuda T, Obara M, Hirano H, Gotoh S, Kubomura S, Higashi K, et al. Analysis of MYCN amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer 1987;60:820-6.
32. Muraji T, Okamoto E, Fujimoto J, Suite S, Nakagawara A. Combined determination of MYCN oncogene amplification and DNA ploidy in neuroblastoma. Cancer 1993;72:2763-8.
33. De Cremoux P, Thioux M, Peter M, Vielh P, Michon J, Delattre O, et al. Polymerase chain reaction compared with dot blotting for the determination of MYCN amplification in neuroblastoma. Int J Cancer 1997;72:518-21.
34. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, et al. Localized neuroblastoma: MYCN amplification is the main prognostic factor-results of the NBL 90 study. J Clin Oncol 1997;15:1171-82.
35. Tanaka T, Seeger RC, Tanabe M, Hiyama E, Shimoda H, Ida N. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification. Cancer Detect Prev 1994;18:283-9.
36. Maggi M, Baldi E, Finetti G, Franceschelli F, Brocchi A, Lanzillotti R, et al. Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res 1994;54:124-33.
37. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 1996;2:1757-65.
38. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, et al. Imaging of somatostatin receptors by Indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385-91.
39. Kogner P, Borgstrom P, Bjellerup P, Schilling FH, Refai E, Jonsson C, et al. Somatostatin in neuroblastoma and ganglioneuroma. Eur J Cancer 1997;33:2084-9.
40. 1 cells. Endocrinology 1995;136:5070-5.
41. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, et al. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995-1008.
42. Vernejoul F, Faure P, Benali N, Cause D, Tiraby G, Pradayrol L, et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002;62:6124-31.
43. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
44. Kumar SK, Goldberg RM. Adjuvant chemotherapy for colon cancer. Curr Oncol Rep 2001;3:94-101.
45. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, et al. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001;44:523-33.
46. Miller GV, Farmery SM, Woodhouse LF, Primrose JN. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer 1992;66:391-5.
47. Radulovic SS, Milovanovic SR, Cai R-H, Schally AV. The binding of bombesin and somatostatin and their analogues to human colon cancers. Proc Soc Exp Biol Med 1992;200:394-401.
48. Reubi JC, Krenning E, Lamberts SWJ, Kvols L. Somatostatin receptors in malignant tissues. J Steroid Biochem Mol Biol 1990;37:1073-7.
49. Dy DY, Morris DL. Somatostatin inhibits both in vitro and in vivo carcinoembryonic antigen secretion by human colon cancer. Eur J Surg Oncol 1993;19:168-72.
50. Dy DY, Withehead RH, Morris DL. SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res 1992;52:917-23.
51. Zerek-melen G, Pawlikowsky M, Winczyk K, Lachowicz-ochedalska A, Legowska A, Kwasny H, et al. Effects of new somatostatin analogues on the cell proliferation of colonic crypts and colonic cancer in rats. Neuropeptides 1993;25:57-60.
52. Di Paolo A, Bocci G, Innocenti F, Agen C, Nardini D, Danesi R, et al. Inhibitory effect of the somatostatin analogue SMS 201.995 and cytokines on the proliferation of human colon adenocarcinoma cell lines. Pharmacol Res 1995;32:135-9.
53. Qin Y, Schally AV, Willems G. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int J Cancer 1992;52:791-6.
54. 125In-Tyr3]octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
55. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, Veeder MH, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 1995;76:961-6.
56. Stewart GJ, Connor JL, Lawson JA, Preketes A, King J, Morris DL. Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Cancer 1995;76:572-8.
57. Cascinu S, Del Ferro E, Catalano G. A randomised trial of octreotide vs. best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br J Cancer 1995;71:97-101.
58. Iftikhar SY, Watson SA, Morris DL. The effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancer. Br J Cancer 1991;63:971-4.
59. Klijn JGM, Hoff AM, Planting AST, Verweij J, Kok TL, Lamberts SWJ, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990;62:627-30.
60. Palmer Smith J, Doll D, Croitoru R, Thornton C, Perry MC. Octreotide has no effect on advanced colon cancer. J Clin Gastroenterol 1994;18:245-7.
61. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823-7.
62. Laws SA, Gough AC, Evans AA, Bains MA, Primrose JN. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 1997;75:360-6.
63. Vuaroqueaux V, Dutour A, Briard N, Monges G, Grino M, Oliver C, et al. No loss of sst receptors gene expression in advanced stages of colorectal cancer. Eur J Endocrinol 1999;140:362-6.
64. Vuaroqueaux V, Dutour A, Bourhim N, Ouafik L, Monges G, Briard N, et al. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma. J Mol Endocrinol 2000;24:397-408.
65. Pinzani P, Orlando C, Casini Raggi C, Cataliotti L, Valanzano R, Tricarico C, et al. Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probes and the TaqmanTM technology. Regul Pept 2001;99:79-86.
66. Casini Raggi C, Calabro A, Renzi D, Briganti V, Cianchi F, Messerini L, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002;8:419-27.
67. Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001;37:1659-67.
68. Harris J, Morrow M, Norton L. Malignant tumors of the breast. In: De Vita Jr, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology; 1997. p. 1557-1616.
69. Prevost G, Provost P, Salle V, Lanson M, Thomas F. A cross-linking assay allows the detection of receptors for the somatostatin analogue lanreotide in human breast tumours. Fur J Cancer 1993;29A:1589-92.
70. Papotti M, Macri L, Bussolati G, Reubi J. Correlative study on neuroendocrine differentiation and presence of somatostatin receptors in breast carcinomas. Int J Cancer 1989;43:365-9.
71. Reubi J, Torhorst J. The relationship between somatostatin. Cancer 1989;64:1254-60.
72. Reubi J, Waser B, Foekens J, Klijn J, Lamberts S, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990;46:416-20.
73. Van Eijck C, Krenning E, Bootsma A, Oei H, Van Pel R, Lindemans J, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994;343:640-3.
74. 111In-octreotide scintigraphy in oncology. Digestion 1993;54:84-7.
75. Schaer J-C, Waser B, Mengod G, Reubi J-C. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 1997;70:530-7.
76. Evans AA, Crook T, Laws SAM, Gough AC, Royle GT, Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997;75:798-803.
77. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455-9.
78. Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res 1998;4:2047-52.
79. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I. Inhibition of human breast cancer cell (MCF7) growth in vitro by the somatostatin analogue SMS201-995 effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991;129:255-6.
80. Prevost G, Foehrle E, Thomas F, Pihan I, Veber N, Starzec A, et al. Growth of human breast cancer cells inhibited by the somatostatin analogue BIM23014 (somatuline). Endocrinology 1991;128:323-30.
81. Scambia G, Benedetti Panici P, Baiocchi P, Perrone L, Iacobelli S, Mancuso S. Antiproliferative effects of somatostatin and somatostatin analogue SMS201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 1988;114:306-8.
82. Setyono-Han B, Henkelman MS, Foekens JA, Klijn JGM. Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987;47:1566-70.
83. Nelson J, Cremin M, Murphy RF. Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. Br J Cancer 1989;59:739-42.
84. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992;52:4973-8.
85. Vennin PH, Peyrat JP, Bonneterre J, Louchez MM, Harris AG, Demaille A. Effect of the long-acting somatostatin analogue SMS201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 1989;9:153-6.
86. Manni A, Boucher AE, Deniers LM, Harvey HA, Lipton A, Simmonds MA, et al. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989;14:289-98.
87. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85:1284-92.
88. Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002;94:299-304.
89. Yu Y, Song J, Berelowitz M, Bruno JF. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996;137:5634-40.
90. Yu Y, Berelowitz M, Bruno JE. Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol Cell Endocrinol 1998;139:71-7.
91. Benali N, Cordelier P, Cause D, Pages P, Rochaix P, Nagy A, et al. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci USA 2000;97:9180-5.
92. Torrisani J, Bouisson M, Puente E, Capella G, Laurent-Puig P, Berger A, et al. Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology 2001;120:200-9.